Form 4: Nuvation Bio Insider Sells Shares Under 10b5-1 Plan

Kerry Wentworth, Chief Regulatory Officer of Nuvation Bio Inc., sold 63,000 shares of Class A Common Stock for $2.93 per share under a pre-arranged 10b5-1 plan.

Summary

• Kerry Wentworth, Chief Regulatory Officer at Nuvation Bio Inc., reported a transaction on June 23, 2026.
• The transaction involved the acquisition of 63,000 shares of Class A Common Stock at a price of $2.93 per share.
• Additionally, 63,000 shares were disposed of under a 10b5-1 plan, with a weighted-average sales price of $6.0189, ranging from $6.00 to $6.08.
• Following these transactions, Wentworth beneficially owns 53,000 shares of Class A Common Stock.
• A stock option to buy 63,000 shares at $2.93, with an expiration date of August 28, 2032, was also part of the reported activity.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a neutral to slightly negative filing due to the significant sale of shares by a key executive, despite the transaction being conducted under a compliant 10b5-1 plan.

Positives

• The sale of shares was conducted under a Rule 10b5-1(c) plan, indicating adherence to pre-determined trading strategies designed to avoid insider trading concerns.
• The reported stock option, acquired under the plan, suggests continued incentive alignment for the reporting person.

Negatives

• A significant number of shares (63,000) were sold by a key executive, which could be perceived negatively by the market.
• The sale price under the 10b5-1 plan ($6.0189 weighted average) is higher than the acquisition price ($2.93), indicating a profitable sale for the executive.

Risks

• The sale of a substantial number of shares by a Chief Regulatory Officer could signal a lack of confidence in the company's near-term prospects, although it was executed under a 10b5-1 plan.
• Potential for negative market perception due to insider selling, even if compliant with trading plans.

Future Outlook

The filing does not contain forward-looking statements or guidance. It solely reports on past transactions.

Industry Context

StockSavvy.ai notes that insider selling, even under a 10b5-1 plan, is a common event in the biotechnology sector. Such transactions are closely watched by investors for potential signals about management's view of the company's valuation and future prospects, though the plan's structure is designed to mitigate concerns about opportunistic trading.

Stakeholder Impact

• Shareholders may interpret the sale of shares by a senior executive as a potential negative signal, although the 10b5-1 plan structure aims to mitigate this.
• Employees may observe insider selling with concern, potentially impacting morale if not adequately contextualized by the company.

Key Dates

Recommendation

The filing reports an insider sale under a 10b5-1 plan, which is a routine transaction. While insider selling can be a negative signal, the pre-planned nature of this transaction under Rule 10b5-1(c) limits its predictive power regarding the company's future performance. Without additional financial or strategic information, a 'hold' recommendation is prudent, pending further developments.

Keywords

Nuvation Bio, NUVB, Form 4, Insider Trading, 10b5-1 Plan, Stock Sale, Class A Common Stock, Kerry Wentworth, Chief Regulatory Officer, Securities Exchange Act